University of Colorado Colorado Springs

About: University of Colorado Colorado Springs is a education organization based out in Colorado Springs, Colorado, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 6664 authors who have published 10872 publications receiving 323416 citations. The organization is also known as: UCCS & University of Colorado at Colorado Springs.

Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens.

Abstract: BACKGROUND. Extended transrectal ultrasound guided biopsies (TRUSB) of the prostate may not accurately convey true morphometric information and Gleason score (GS) of prostate cancer (PCa) and the clinical use of template-guided (5-mm grid) transperineal mapping biopsies (TPMBs) remains controversial. METHODS. We correlated the clinical-pathologic results of 1,403 TPMB cores obtained from 25 men diagnosed with PCa with 64 cancer lesions found in their corresponding radical prostatectomy (RP) specimens. Special computer models of three-dimensional, whole-mounted radical prostatectomy (3D-WMRP) specimens were generated and used as gold standard to determine tumor morphometric data. Between-sample rates of upgrade and downgrade (highest GS and a novel cumulative GS) and upstage and downstage (laterality) were determined. Lesions � 0.5 cm 3 or GS � 7 were considered clinically significant. RESULTS. From 64 separate 3D-WMRP lesions, 25 had significant volume (mean 1.13 cm 3 ) and 39 were insignificant (mean 0.09 cm 3 )( P < 0.0001); 18/64 lesions were missed by TPMB, but only one was clinically significant with GS-8 (0.02 cm 3 ). When comparing the cumulative GS of TPMB versus RP, 72% (n ¼ 18) had identical scores, 12% (n ¼ 3) were upgraded, and only 16% (n ¼ 4) were downgraded. Laterality of TPMB and RP was strongly correlated, 80% same laterality, 4% were up-staged, and 16% down-staged. CONCLUSIONS. Our clinical-pathology correlation showed very high accuracy of TPMB with a 5-mm grid template to detect clinically significant PCa lesions as compared with 3D-WMRP, providing physicians and patients with a reliable assessment of grade and stage of disease and the opportunity to choose the most appropriate therapeutic options.

Public Transportation: An Investigation of Barriers for People With Disabilities:

Abstract: The physical accessibility of public transportation increased nationwide following the passage of the Americans With Disabilities Act (ADA) in 1990. Despite removal of many physical barriers within...

On the importance of matching strategic behavior and target market selection to business strategy in high-tech markets

Abstract: Business strategy is fundamentally concerned with the actions required to create superior customer value in the firm’s target markets with the ultimate goal of achieving superior performance. Marketing theory suggests that two critical marketing activities required to achieve this end are: (1) the adoption of appropriate strategic behaviors (i.e., customer-oriented, competitor-oriented, technology-oriented) and (2) targeting of the appropriate market segments (i.e., innovators, early adopters, early majority, late majority, laggards). This study builds on prior research which demonstrates that the strategic behavior—firm performance relationship is contingent on the firm’s strategy by examining this relationship in high tech markets and by considering the incremental contribution of appropriate target market selection. Responses from 160 senior marketing managers in high-tech firms reveal strong support for our framework. Thus, this study provides useful guidance to executives and managers in high-tech firms regarding the steps that they should take to increase their probability of success.

Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.

Abstract: Purpose: Uterine-serous-carcinoma (USC) is an aggressive variant of endometrial cancer On the basis of preliminary results of a multicenter, randomized phase II trial, trastuzumab (T), a humanized-mAb targeting Her2/Neu, in combination with carboplatin/paclitaxel (C/P), is recognized as an alternative in treating advanced/recurrent HER2/Neu-positive USC We report the updated survival analysis of NCT01367002 Patients and Methods: Eligible patients had stage III to IV or recurrent disease Participants were randomized 1:1 to receive C/P for six cycles ± T followed by maintenance T until progression or toxicity Progression-free survival (PFS) was the primary endpoint; overall survival (OS) and toxicity were secondary endpoints Results: Sixty-one patients were randomized After a median-follow-up of 259 months, 43 progressions and 38 deaths occurred among 58 evaluable patients Updated median-PFS continued to favor the T-arm, with medians of 80 months versus 129 months in the control and T-arms (HR = 046; 90% CI, 028–076; P = 0005) Median-PFS was 93 months versus 177 months among 41 patients with stage III to IV disease undergoing primary treatment (HR = 044; 90% CI, 023–083; P = 0015), and 70 months versus 92 months among 17 patients with recurrent disease (HR = 012; 90% CI, 003–048; P = 0004) OS was higher in the T compared with the control arm, with medians of 296 months versus 244 months (HR = 058; 90% CI, 034–099; P = 0046) The benefit was most notable in those with stage III to IV disease, with survival median not reached in the T-arm versus 244 months in the control arm (HR = 049; 90% CI, 025–097; P = 0041) Toxicity was not different between arms Conclusions: Addition of T to C/P increased PFS and OS in women with advanced/recurrent HER2/Neu-positive USC, with the greatest benefit seen for the treatment of stage III to IV disease